medigraphic.com
ISSN 2078-7170 (Electronic)

2012, Number 1

<< Back Next >>

CorSalud 2012; 4 (1)

Clinical-developmental behavior of hypertensive patients treated at the outpatient department of

Hoyo PHA, Ledesma SE, Rodríguez AAM, Castañeda CL, Moreno-Martínez FL

Language: Spanish
References: 52
Page: 6-19
PDF size: 294.13 Kb.


ABSTRACT

Introduction and objectives: Hypertension is responsible for a significant number of cardiovascular complications and their incidence is increasing. The objective of this research was to characterize the clinical-developmental behavior of hypertensive patients treated at the outpatient department. Method: A prospective intervention study was performed with 413 patients treated for hypertension at the outpatient department of "Celestino Hernández Robau" University Hospital in Santa Clara, between January 9th, 2007 and July 15th, 2008. Variables such as sex, age group, classification of hypertension, presentation forms, electrocardiographic changes, complications, cardiovascular risk factors and therapeutic effectiveness were evaluated. Results: The frequency of hypertension was 23 % with a mean age of 62 years and no significant differences regarding gender. 14,0 % presented isolated systolic hypertension and 78,0 % moderate to severe hypertension. At diagnosis, left ventricular hypertrophy in 28 % of patients was found. A significant association between moderate to severe hypertension and the frequency of complications was found. 18,6 % of patients were diabetic, 19,6 % presented hypercholesterolemia and 31,7 % met diagnostic criteria for metabolic syndrome. Conclusions: The high prevalence of hypertension is a serious health problem, all the more so as a high incidence of moderate and severe hypertension associated with HIV was found, as well as other clinical elements that show involvement of other organs. All applied therapeutic options were equally effective in achieving BP control, regardless of the type of drug association. It is necessary to design and generalize promotion programs in the community to ensure adequate control of modifiable risk factors.


REFERENCES

  1. Rodrigues Barbosa A, Ferreti Borgatto A. Arterial Hypertension in the Elderly of Bridgetown, Barbados: Prevalence and Associated Factors. J Aging Health. 2010;22(5):611-30.

  2. Llisterri JL, Morillas P, Pallarés V, Fácila L, Sanchís C, Sánchez T; FAPRES researchers. [Differences in the degree of control of arterial hypertension according to the measurement procedure of blood pressure in patients ≥ 65 years. FAPRES study]. Rev Clin Esp. 2011 Feb;211(2):76-84. Spanish.

  3. Moreno-Martínez FL, Escobar Blanco A, Díaz López F, Alegret Rodríguez M, López-Bernal OJ, Aladro Miranda I, et al. Factores de riesgo coronario y riesgo cardiovascular en personas adultas de un área de salud de Rancho Veloz (Cuba). Clin Invest Arterioscl. 2008;20(4):151-61.

  4. Caballero López A. Terapia Intensiva. La Habana: ECIMED; 2006.

  5. Rabetti Ade C, Freitas SF. Evaluation of actions concerning systemic arterial hypertension in primary healthcare. Rev Saude Publica. 2011r;45(2):258-68.

  6. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206-52.

  7. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents. Pediatrics 2004; 114 (2 Suppl 4th Report):555-76.

  8. Dilic M, Dzubur A, Kusljugic Z, Balic S, Pepic E. Correlation of arterial hypertension and type 2 diabetes mellitus with type of polyvascular atherosclerotic disease. Med Arh. 2010;64(5):264-8.

  9. Novgorodtseva TP, Kantur TA, Karaman YK, Antonyuk MV, Zhukova NV. Modification of fatty acids composition in erythrocytes lipids in arterial hypertension associated with dyslipidemia. Lipids Health Dis. 2011;10:18.

  10. Moreno Martínez FL, López Bernal OJ, Llanes Pelegrín RJ, Cepero Franco S, Rodríguez Oliva N. Obesidad: aspectos patogénicos, alteraciones cardiovasculares asociadas y estrategias terapéuticas. Mapfre Medicina. 2005;16(3):209-22.

  11. Moreno-Martínez FL. Obesidad y distribución regional de la grasa: viejos temas con nuevas reflexiones. CorSalud [Internet] 2011 [citado 6 Dic 2011]; 3(1):[aprox. 2 p].Disponible en: http://www.corsalud.sld.cu/sumario/2011/v3n1a11/di stribucion.htm

  12. Aladro Miranda IF. Evaluación clínica, eléctrica y ecocardiográfica de pacientes sometidos a angioplastia coronaria con implantación de stent [Trabajo de terminación de especialidad]. Hospital Universitario “Celestino Hernández Robau”. Villa Clara: UCM; 2007.

  13. Gosse P, Coulon P, Papaioannou G, Litalien J, Lemetayer P. Impact of malignant arterial hypertension on the heart. J Hypertens. 2011;29(4):798-802.

  14. Bakalli A, Koçinaj D, Bakalli A, Krasniqi A. Relationship of hypertensive retinopathy to thoracic aortic atherosclerosis in patients with severe arterial hypertension. Clin Exp Hypertens. 2011;33(2):89-94.

  15. López-Jaramillo P, Rueda-Clausen CF, Ramírez F, Saaibi F, Balestrini S, García RG, et al. Las diferencias en los criterios diagnósticos de síndrome metabólico son útiles para identificar sujetos en riesgo, pero pierden relevancia en pacientes con enfermedad coronaria. Rev Colomb Cardiol. 2006;13(1):28- 35.

  16. Grundy SM. Metabolic Syndrome: Connecting and Reconciling Cardiovascular and Diabetes Worlds. JACC. 2006;47(6):1093-100.

  17. Roméu Escobar M, Sabina Molina D, Sabina Roméu B. Evaluación del paciente hipertenso. Experiencia de la consulta especializada en hipertensión arterial. MediSur [Internet]. 2005 [citado 6 Sept 2010];3(2):[aprox. 3 p.]. Disponible en: http://www.medisur.sld.cu/index.php/medisur/article/ view/101

  18. Neglia D, Fommei E, Varela-Carver A, Mancini M, Ghione S, Lombardi M, et al. Perindopril and indapamide reverse coronary microvascular remodelling and improve flow in arterial hypertension. J Hypertens. 2011;29(2):364-72.

  19. D’Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care. The Framingham Heart Study. Circulation. 2008;117(6): 743-53.

  20. Matheson KM, Cutting JE, Mazurak VC, Robinson LE, Buchholz AC. n-3 Polyunsaturated Fatty Acids Increase Thermic Effect of Food in Men with Metabolic Syndrome. Can J Diet Pract Res. 2011; 72(4):201-4.

  21. Ljubotina A, Materljan E, Mićović V, Kapović M, Stefanac-Nadarević V, Ivosević D. Perception of arterial hypertension and myocardial infarction in hypertensive and normotensive men and women. Coll Antropol. 2011;35(1):147-53.

  22. Bojar I, Humeniuk E, Owoc A, Wierzba W, Wojtyła A. Exposing women to workplace stress factors as a risk factor for developing arterial hypertension. Ann Agric Environ Med. 2011;18(1):175-82.

  23. Parkinson AB, Evans NA. Anabolic androgenic steroids: a survey of 500 users. Med Sci Sports Exerc. 2006;38(4):644-51.

  24. Tycinska AM, Mroczko B, Musial WJ, Sawicki R, Kaminski K, Borowska H, et al. Blood pressure in relation to neurogenic, inflammatory and endothelial dysfunction biomarkers in patients with treated essential arterial hypertension. Adv Med Sci. 2011; 56(1):80-7.

  25. De Pergola G, Nardecchia A, Guida P, Silvestris F. Arterial hypertension in obesity: relationships with hormone and anthropometric parameters. Eur J Cardiovasc Prev Rehabil. 2011;18(2):240-7.

  26. Stoicescu M, Csepento C, Muţiu G, Bungău S. The role of increased plasmatic renin level in the pathogenesis of arterial hypertension in young adults. Rom J Morphol Embryol. 2011;52(1 Suppl): 419-23.

  27. Hernández R, Armas MC, Armas MJ, Velasco M. Hipertensión y Salud Cardiovascular en Venezuela y Países Latinoamericanos. J Hum Hypertens. 2000;14(1):2-5.

  28. Pickering T, Schwartz J, Verdecchia P, Imai Y, Kario K, Eguchi K, et al. Prediction of strokes versus cardiac events by ambulatory monitoring of blood pressure: results from an international database. Blood Press Monit. 2007;12 (6):397-9.

  29. Hajjar I, Yang F, Sorond F, Jones RN, Milberg W, Cupples LA, et al. A novel aging phenotype of slow gait, impaired executive function, and depressive symptoms: relationship to blood pressure and other cardiovascular risks. J Gerontol A Biol Sci Med Sci. 2009;64(9):994-1001.

  30. Franklin SS, Larson MG, Khan SA, Wong ND, Leip EP, Kannel WB, et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation. 2001;103(9):24-59.

  31. Twagirumukiza M, De Bacquer D, Kips JG, de Backer G, Stichele RV, Van Bortel LM. Current and projected prevalence of arterial hypertension in sub- Saharan Africa by sex, age and habitat: an estimate from population studies. J Hypertens. 2011;29(7): 1243-52.

  32. Young CH, Zhang K, Poret AW. Patterns of antihypertensive therapy in new users of angiotensin IIreceptor blockers. Am J Health-System Pharmacy. 2005;62(22):2381-5.

  33. Glancy DL, Heck HA, Jain N, Jaligam VR, Rodriguez JF, Nijjar VS, et al. Preoperative ECG in a woman with systemic hypertension, diabetes melli tus, smoking, and severe coronary and peripheral arterial disease. Left atrial enlargement. Right bundle branch block with marked right axis deviation (+130 degrees) due to left posterior fascicular block. J La State Med Soc. 2010;162(3):126-8.

  34. Guarino F, Cantarella G, Caruso M, Russo C, Mancuso S, Arcidiacono G, et al. Endothelial activation and injury by cigarette smoke exposure. J Biol Regul Homeost Agents. 2011;25(2):259-68.

  35. Davis BR, Cutler JA, Gordon DJ, Furberg CD, Wright JT Jr, Cushman WC, et al. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial(ALLHAT). Am J Hypertens. 2004;9(4 Pt 1):342-60.

  36. Williams B. Drug treatment of hypertension. BMJ. 2003;326 (7380):61-2.

  37. Urquhart J. Patient non-compliance with drug regimens: measurement, clinical correlates, economic impact. Eur Heart J. 2006;17 Suppl A:8-15.

  38. Dilic M, Dzubur A, Kusljugic Z, Balic S, Pepic E. Correlation of arterial hypertension and type 2 diabetes mellitus with type of polyvascular atherosclerotic disease. Med Arh. 2010;64(5):264-8.

  39. Madden KM, Lockhart C, Potter TF, Cuff D. Aerobic training restores arterial baroreflex sensitivity in older adults with type 2 diabetes, hypertension, and hypercholesterolemia. Clin J Sport Med. 2010;20(4): 312-7.

  40. Morales-Suárez-Varela MM, Mansego ML, Vicedo- Cabrera AM, Pineda-Alonso M, Llopis-González A, Martin-Moreno JM, et al. Inefficient arterial hypertension control in patients with metabolic syndrome and its link to renin-angiotensin-aldosterone system polymorphisms. Hypertens Res. 2011;34(6):758-66.

  41. De Vecchis R, Ciccarelli A, Ariano C, Cioppa C, Giasi A, Pucciarelli A, et al. The relation between carotid atherosclerotic plaques and ischemic stroke is critically conditioned by the role of arterial hypertension as an effect modifier. Can J Cardiol. 2011;27(2):152-8.

  42. Ninomiya JK, L’talien G, Criqui MH, Whyte JL, Gamst A, Chen RS. Association of the metabolic syndrome with history of myocardial infarction and stroke in the third national health and nutrition examination survey. Circulation. 2004;109(1):42-6.

  43. Franklin SS, Larson MG, Khan SA, Wong ND, Leip EP, Kannel WB, et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation. 2001;103(9):124-59.

  44. Ramírez M, Moreno-Martínez FL, Torres D, Nieto CG, Osorio CM, Guevara A, et al. Detección de hipertrofia ventricular izquierda en adolescentes con hipertensión arterial esencial. Hipertensión (Madr). 2006;23(9):277-83.

  45. Veronese P, Benvenuti LA. 59-year-old male patient with severe obesity, arterial hypertension and heart failure submitted to anticoagulation therapy for atrial fibrillation, presented cerebrovascular accident and septicemia. Arq Bras Cardiol. 2010;94(2):264-70.

  46. Appel LJ, Champagne CM, Harsha DW, Cooper LS, Obarzanek E, Elmer PJ, et al. Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. Writing Group of the PREMIER Collaborative Research Group. JAMA. 2003;289(16):2083-93.

  47. Alvarez-Alvarez B, Abad-Cardiel M, Fernandez- Cruz A, Martell-Claros N. Management of resistant arterial hypertension: role of spironolactone versus double blockade of the renin-angiotensin-aldosterone system. J Hypertens. 2010;28(11):2329-35.

  48. Frishman WH, Bryzinski BS. A multifactorial design to assess combination therapy in hypertension. Arch Intern Med. 2004;154(13):1463-70.

  49. The Heart Outcomes Prevention Evaluation Study Investigators, Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med. 2000;342:145- 53.

  50. Bisognano JD, McLaughlin T, Roberts CS, Tang SS. Calcium channel blockers, angiotensin receptor blockers, and angiotensin-converting enzyme inhibitors: effectiveness in combination with diuretics or beta-blockers for treating hypertension. Vasc Health Risk Manag. 2007;3(5):579-85.

  51. López Casanova A, Triana de la Paz R, Pérez Fernández GA. Factores relacionados con la urgencia hipertensiva en un área de salud urbana de Santa Clara. CorSalud [Internet] 2009 [citado 8 Mar 2010];1(4):[aprox. 5 p.]. Disponible en: http://bvs.sld.cu/revistas/cors/sumario/2009/v1n4a0 9/factoresarreglado.htm

  52. Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, et al; The Second Australian National Blood Pressure Study Group. A Comparison of Outcomes with Angiotensin - Converting - Enzyme Inhibitors and Diuretics for Hypertension in the Elderly. N Engl J Med. 2003;348(7):583-92.




2020     |     www.medigraphic.com